Gold mining stocks plunge again to new recent lows; industry insiders: Q2 may present investment opportunities

金十2026/03/16 04:55

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Golden Ten Data reported on March 16 that tensions in the Middle East have not eased, and gold prices as well as gold mining stocks are once again attracting attention. Recently, gold mining stocks have significantly underperformed gold itself. According to interviewed industry insiders, the weakness in gold mining stocks is not only due to company operational issues, but also because the tense situation in the Middle East has caused oil prices to soar, triggering inflation. This may lead central banks such as the Federal Reserve to be more cautious in their approach to interest rate cuts, which is bearish for gold. It is expected that gold will continue to face adjustment pressure in the short term. However, the second quarter may present an opportunity for allocation, as central banks continue to purchase gold and other fundamental factors supporting medium- and long-term growth remain. Cen Zhiyong, an analyst at Wutong Research Institute, stated that gold mining stocks fluctuate not only with gold prices, but also involve company operations, debt issues, and stock market sentiment, all of which affect stock prices. In addition, the recent rise in oil prices has pushed up inflation, making it difficult for the Federal Reserve to cut interest rates, and even creating pressure to raise rates, which is also a negative factor for gold prices.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11